352 related articles for article (PubMed ID: 37509724)
1. Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors.
Frąk W; Hajdys J; Radzioch E; Szlagor M; Młynarska E; Rysz J; Franczyk B
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509724
[TBL] [Abstract][Full Text] [Related]
2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes.
Siamashvili M; Davis SN
Expert Opin Pharmacother; 2021 Nov; 22(16):2181-2198. PubMed ID: 34388350
[TBL] [Abstract][Full Text] [Related]
4. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
5. Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches.
Xu J; Hirai T; Koya D; Kitada M
J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011882
[TBL] [Abstract][Full Text] [Related]
6. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
7. Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes.
Derosa G; Maffioli P
Ther Clin Risk Manag; 2018; 14():1637-1640. PubMed ID: 30237717
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
9. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose Cotransporter 2 Inhibitors' Rise to the Backbone of Heart Failure Management: A Clinical Review.
Rohant N; Kennedy JL
Heart Int; 2021; 15(1):42-48. PubMed ID: 36277321
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis.
Tian L; Ai S; Zheng H; Yang H; Zhou M; Tang J; Liu W; Zhao W; Wang Y
Front Pharmacol; 2022; 13():986186. PubMed ID: 36506550
[TBL] [Abstract][Full Text] [Related]
12. The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.
Gallwitz B
Eur Endocrinol; 2018 Apr; 14(1):17-23. PubMed ID: 29922347
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review.
Giri Ravindran S; Kakarla M; Ausaja Gambo M; Yousri Salama M; Haidar Ismail N; Tavalla P; Uppal P; Mohammed SA; Rajashekar S; Hamid P
Cureus; 2022 May; 14(5):e25476. PubMed ID: 35800782
[TBL] [Abstract][Full Text] [Related]
14. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
Mende CW
Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
[TBL] [Abstract][Full Text] [Related]
15. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
Nakagawa Y; Kuwahara K
J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
Vivian EM
Drugs Context; 2014; 3():212264. PubMed ID: 25598831
[TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease.
Aftab S; Vetrivel Suresh R; Sherali N; Daniyal M; Tsouklidis N
Cureus; 2020 Oct; 12(10):e10783. PubMed ID: 33042651
[TBL] [Abstract][Full Text] [Related]
18. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Patel K; Carbone A
Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
[No Abstract] [Full Text] [Related]
19. A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors.
Chaurasia PP; Dholariya S; Kotadiya F; Bhavsar M
Cureus; 2021 Sep; 13(9):e18300. PubMed ID: 34722075
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
